Splash Beverage Group (NYSE American: SBEV) is set to undergo a significant transformation, rebranding as Endovia Health Sciences and adopting the ticker symbol EDVA, effective August 21, 2026. This strategic pivot marks a decisive move away from its legacy beverage operations towards a diversified platform focused on cannabinoid health sciences, complete with the launch of EndoviaSciences.com.
The company has structured its future growth around three core pillars: commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and consumer cannabinoid wellness and beverage products. Management indicates that recent strategic maneuvers, including the acquisition of valuable cannabinoid pharmaceutical intellectual property and the cultivation of international commercialization opportunities, are designed to underpin this ambitious long-term vision and mission.
Key Takeaways
- Corporate identity will evolve to Endovia Health Sciences (EDVA), effective August 21, 2026.
- The company is repositioning as a diversified cannabinoid health sciences platform, centered on three strategic growth pillars.
- Key recent actions include acquiring pharmaceutical IP and pursuing international market access for cannabinoid-based products.
Rebrand Effective Date
August 21, 2026
Official transition for corporate name and ticker
Strategic Repositioning Period
6 months
Management’s timeframe for executing the transformation
Growth Pillars
3
Key areas of focus for the new platform strategy
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 05 | Veterinary partnership | Positive | +21.4% | Lupvindol collaboration advanced CannEpil through an FDA veterinary development pathway. |
| Jul 29 | Veterinary expansion | Positive | -9.3% |
CannEpil license expansion created a second FDA-regulated veterinary development platform. |
| Jul 14 | Balance sheet update | Positive | -15.9% |
Debt settlements and reverse-split approval supported the company’s compliance strategy. |
| Jul 09 | Compliance plan | Positive | -5.0% |
NYSE American accepted a compliance plan extending the listing period. |
| Jul 07 | CannEpil license | Positive | -23.2% |
Exclusive global CannEpil rights added pharmaceutical development and commercialization potential. |
Recent strategic announcements have shown a pattern of negative short-term market reactions in four out of five instances, despite positive underlying sentiment for the initiatives themselves.
intellectual property
technical
“acquiring differentiated pharmaceutical intellectual property”
Intellectual property refers to creations of the mind, such as inventions, literary and artistic works, designs, and symbols, names, and images used in commerce. In a business context, robust IP portfolios are critical for establishing competitive advantages, securing market exclusivity, and driving valuation. For investors, IP represents intangible assets that can generate significant future revenue streams through licensing, patent protection, and preventing market erosion by competitors. The strategic acquisition of IP in the pharmaceutical and health sciences sector is a key indicator of a company’s commitment to innovation and its potential for long-term profitability and market leadership.
AI-generated analysis. Not financial advice.
New corporate identity reflects Company’s strategic evolution into a diversified cannabinoid health sciences platform
Splash Beverage Group, Inc. (NYSE American: SBEV) today announced its intention to change its corporate name to Endovia Health Sciences, Inc., effective August 21, 2026. Concurrently, the Company will transition to the ticker symbol “EDVA” and launch EndoviaSciences.com as part of its comprehensive rebranding initiative.
This strategic name change signifies a fundamental transformation of the Company, moving beyond its established beverage operations to embrace a diversified cannabinoid health sciences platform. The new direction is sharply focused on the commercialization of pharmaceutical assets, the advancement of FDA-regulated human and veterinary therapeutics, and the development of innovative cannabinoid wellness and beverage products.
“This rebranding is more than a mere name change; it represents the culmination of a carefully orchestrated strategic transformation,” stated Brady Cobb, Interim Chief Executive Officer of Splash Beverage Group.
Cobb elaborated, “Over the past six months, we have systematically repositioned the Company by acquiring unique pharmaceutical intellectual property, establishing international commercialization pathways, expanding into FDA-regulated veterinary therapeutics, and assembling a highly experienced team dedicated to cannabinoid pharmaceutical development. Endovia Health Sciences accurately reflects both our current operational reality and our future aspirations.”
Building a Diversified Cannabinoid Health Sciences Platform
Endovia Health Sciences is architecting its future growth strategy around three synergistic business segments, designed to generate multiple avenues for sustained long-term expansion and enhanced shareholder value.
Commercial Pharmaceutical Assets
This segment will focus on the commercialization of differentiated cannabinoid pharmaceutical products through a robust strategy encompassing international distribution networks, strategic partnerships, and targeted licensing opportunities.
FDA-Regulated Human & Veterinary Therapeutics
The Company intends to advance proprietary cannabinoid medicines through established regulatory pathways, targeting both human health applications and the companion animal market.
Consumer Wellness & Beverages
This pillar involves the development of innovative cannabinoid-infused wellness products and beverages, strategically positioned to capitalize on evolving regulatory frameworks and emerging market demands.
This diversified strategic approach is designed to be capital-efficient, fostering long-term enterprise value by leveraging a common foundation of cannabinoid science, intellectual property, and commercial execution expertise.
Our Vision
To establish Endovia Health Sciences as the preeminent global leader in cannabinoid health sciences, dedicated to developing, commercializing, and advancing innovative therapies and wellness solutions that demonstrably improve the quality of life for individuals and animals worldwide.
Our Mission
Endovia Health Sciences is committed to the strategic acquisition, development, and commercialization of differentiated cannabinoid health technologies across pharmaceutical, veterinary, and consumer wellness markets. Through disciplined capital allocation, unwavering scientific excellence, and synergistic strategic partnerships, we aim to build scalable and sustainable businesses that deliver meaningful healthcare innovation and robust long-term shareholder value.
“We firmly believe that cannabinoids represent one of the most promising frontiers in modern health sciences,” Cobb emphasized.
“Our core mission is to responsibly unlock this potential through a commitment to scientific innovation, strategic collaborations, and disciplined execution. Every acquisition, every partnership, and every investment we undertake is meticulously planned to strengthen our market position as a leading cannabinoid health sciences company and to generate enduring value for patients, consumers, partners, and shareholders alike.”
Looking Ahead
The forthcoming rebrand to Endovia Health Sciences is expected to coincide with the unveiling of a new corporate website, updated investor relations materials, and a cohesive corporate identity that effectively communicates the company’s long-term strategic vision.
As Endovia Health Sciences, the Company is poised to continue its portfolio expansion through strategic acquisitions, commercial partnerships, regulated pharmaceutical development initiatives, and the creation of innovative consumer health products. All these efforts will be unified under the advancement of cannabinoid science, driven by disciplined operational execution.
“Our strategic focus is unequivocally clear,” Cobb concluded. “We are building a science-driven organization characterized by differentiated intellectual property, seasoned leadership, and multiple sustainable growth trajectories. We are confident that Endovia Health Sciences signifies the commencement of an exceptionally promising new chapter for our shareholders, our partners, and ultimately, the patients and consumers we serve.”
About Endovia Health Sciences
Endovia Health Sciences is meticulously constructing a diversified cannabinoid health sciences platform. Its strategic focus centers on the acquisition, development, and commercialization of differentiated cannabinoid health technologies spanning the pharmaceutical, veterinary, and consumer wellness sectors.
Where Science Meets Cannabinoid Innovation
Frequently Asked Questions
When will Splash Beverage Group (NYSE American: SBEV) change its name to Endovia Health Sciences and ticker to EDVA?
Splash Beverage Group is scheduled to officially change its corporate name to Endovia Health Sciences and its ticker symbol to EDVA on August 21, 2026. This rebranding initiative will also feature the launch of a new corporate website and updated investor communications, according to company statements.
Why is Splash Beverage Group (SBEV) rebranding to Endovia Health Sciences?
The rebranding reflects Splash Beverage Group’s strategic evolution from a conventional beverage company into a comprehensive cannabinoid health sciences platform. The company’s new focus encompasses pharmaceutical assets, FDA-regulated therapeutics for humans and animals, and innovative cannabinoid wellness and beverage products, signaling a significant shift in its core business direction.
What is the new strategic focus of Endovia Health Sciences (EDVA) after the SBEV rebrand?
Endovia Health Sciences will concentrate on three primary areas: commercializing cannabinoid pharmaceutical assets, developing FDA-regulated human and veterinary therapeutics, and creating consumer cannabinoid wellness and beverage products. This diversified strategy is designed to leverage shared cannabinoid science and intellectual property to build long-term enterprise value.
What recent steps has Splash Beverage Group (SBEV) taken to build Endovia Health Sciences?
Over the past six months, the company has actively acquired differentiated pharmaceutical intellectual property and secured international commercialization opportunities. Furthermore, it has expanded its presence in FDA-regulated veterinary therapeutics and assembled a specialized team for cannabinoid pharmaceutical development to support the new platform.
What is the mission and vision of Endovia Health Sciences (EDVA) after the SBEV rebranding?
Endovia’s vision is to become a global leader in cannabinoid health sciences, aiming to improve lives through innovative therapies. Its mission is to acquire, develop, and commercialize differentiated cannabinoid health technologies through strategic partnerships, scientific excellence, and disciplined capital allocation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements concerning the Company’s rebranding, strategic focus, development and commercialization efforts for human and animal medicinal products, anticipated market trends, growth expectations, and plans for portfolio expansion. These statements are subject to risks and uncertainties that could cause actual results to differ materially. Such risks include, but are not limited to, the Company’s ability to secure necessary financing, meet contractual obligations including licensing terms, obtain regulatory approvals, protect intellectual property, and compete effectively in the market. Furthermore, the success of the Company’s business plan and strategic transactions is subject to various contingencies and uncertainties. Additional information regarding these risks can be found in the Company’s filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update forward-looking statements except as required by law.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/24740.html
